Last €0.02 EUR
Change Today +0.002 / 9.52%
Volume 0.0
E4N On Other Exchanges
Symbol
Exchange
Frankfurt
As of 3:18 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

suda ltd (E4N) Snapshot

Open
€0.02
Previous Close
€0.02
Day High
€0.02
Day Low
€0.02
52 Week High
10/29/14 - €0.05
52 Week Low
01/29/15 - €0.02
Market Cap
22.6M
Average Volume 10 Days
2.0K
EPS TTM
--
Shares Outstanding
984.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUDA LTD (E4N)

Related News

No related news articles were found.

suda ltd (E4N) Related Businessweek News

No Related Businessweek News Found

suda ltd (E4N) Details

Suda Limited engages in the pharmaceutical development of drug delivery technologies in Australia. The company is developing ArTiMist malaria, a sub-lingual spray that has completed Phase III clinical trial for the treatment of p. falciparum severe paediatric malaria. Its product candidates also include SUD-001, a honey-flavoured oral spray formulation of sumatriptan; SUD-002, a mint-flavoured oral spray formulation of ondansetron to treat nausea and vomiting induced by chemotherapy or radiotherapy, and other post-operative settings; and SUD-003, an oral spray formulation of sildenafil sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction. In addition, the company is developing SUD-004, an oral spray formulation of sildenafil to treat pulmonary arterial hypertension in adults; and SUD-005, a strawberry/mint-flavoured oral spray formulation of midazolam for the treatment of pre-procedure anxiety in imaging and dental procedures, and in the treatment of epileptic seizures. Further, it distributes medical devices and consumables to hospitals, aged care facilities, pharmacies, mining companies, and other healthcare providers. The company was formerly known as Eastland Medical Systems Limited and changed its name to Suda Limited in December 2012. Suda Limited is based in Osborne Park, Australia.

27 Employees
Last Reported Date: 09/26/14

suda ltd (E4N) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: A$238.4K
Chief Financial Officer, Company Secretary, E...
Total Annual Compensation: A$193.8K
Chief Business Officer
Total Annual Compensation: A$116.0K
General Manager of Westcoast
Total Annual Compensation: A$133.8K
Compensation as of Fiscal Year 2014.

suda ltd (E4N) Key Developments

SUDA Ltd and Amherst in Licence and Collaboration Agreement

SUDA Ltd. have entered a cross-licence and collaboration agreement to develop and commercialise SUDA's oral spray of ondansetron (SUD-002) for the treatment of nausea and vomiting induced by chemotherapy or radiotherapy, and Amherst's oral spray of zolpidem tartrate (Zolpimist) for insomnia. Under the terms of the agreement, SUDA is granting Amherst an exclusive licence to manufacture, develop and commercialise SUD-002 in the Americas and South Africa. SUDA receives an exclusive licence to manufacture, develop and commercialise Zolpimist in all territories excluding the Americas and South Africa. Both parties have the right to sub-license in their respective territories.

SUDA Ltd and Amherst Pharmaceuticals Enter a Cross-Licence and Collaboration Agreement

SUDA Ltd. and Amherst Pharmaceuticals have entered a cross-licence and collaboration agreement to develop and commercialise SUDA's oral spray of ondansetron (SUD-002) for the treatment of nausea and vomiting induced by chemotherapy or radiotherapy, and Amherst's oral spray of zolpidem tartrate (Zolpimist)for insomnia. Under the terms of the agreement, SUDA is granting Amherst an exclusive licence to manufacture, develop and commercialise SUD-002 in the Americas and South Africa. SUDA receives an exclusive licence to manufacture, develop and commercialise Zolpimist in all territories excluding the Americas and South Africa. Both parties have the right to sub-license in their respective territories. SUDA is entitled to a 6% to 12% share of income from Amherst's commercialisation of SUD-002 in the Americas and South Africa. Similarly, Amherst will receive a 6% to 12% share of income from SUDA's commercialisation of Zolpimist in SUDA's territories.

Suda Ltd, Annual General Meeting, Nov 27, 2014

Suda Ltd, Annual General Meeting, Nov 27, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
E4N:GR €0.02 EUR +0.002

E4N Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for E4N.
View Industry Companies
 

Industry Analysis

E4N

Industry Average

Valuation E4N Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUDA LTD, please visit www.sudaltd.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.